Coherus Oncology Inc (CHRS)

R&D Expense Growth

3.78%

Quarterly · Period ending:

CHRS logo

CHRS R&D Expense Growth

Latest reported3.78%
CHRS Quarterly R&D Growth (QoQ) (0.00% → 3.78%)
High-resolution chart · PNG

CHRS r&d expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc R&D Expense Growth — Quarterly
Period endingR&D Expense Growth
3.775%
-31.3053%
14.4259%
3.9383%
8.4942%
9.7716%
-2.0345%
4.3721%
-26.935%
7.7973%
2.8112%
10.2291%
-31.8762%
17.6831%
-36.6443%
10.0863%
-49.8161%
63.3446%
-6.144%
-1.2435%
-73.0869%
355.9738%
14.8696%
48.4392%
-20.9442%
-5.2678%
62.0364%
14.2191%
0.5003%
-29.5289%
-15.6346%
19.1712%
4.1799%
-19.1597%
-26.1296%
23.5536%
-35.8438%
-8.8714%
-8.6151%
-1.4814%
0.3537%
26.9866%
-24.6049%
19.7984%
56.1521%
35.7316%
45.2584%
-2.2668%
35.7994%
51.1169%
86.9072%
-44.976%
3.5929%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.